| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T65197 | ||||
| Target Name | Erythropoietin Receptor | ||||
| Target Type | Successful |
||||
| Drug Potency against Target | Epoetin alfa | Drug Info | EC50 = 0.138 nM | [552410] | |
| Darbepoetin alfa | Drug Info | EC50 = 0.703 nM | [552410] | ||
| Action against Disease Model | Darbepoetin alfa | Further, relative biologic activity, measured by determining in vitro proliferation effects of both agents on the UT7/EPO cell line, indicated that the effective ligand concentration to obtain 50% biologic activity (EC50) was 0.0589 nM for darbepoetin alfa | [552553] | Drug Info | |
| Epoetin alfa | Further, relative biologic activity, measured by determining in vitro proliferation effects of both agents on the UT7/EPO cell line, indicated that the effective ligand concentration to obtain 50% biologic activity (EC50) was 0.0115 nM for epoetin alfa. | [552410] | Drug Info | ||
| References | |||||
| Ref 552553 | CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005 Nov;4(6):436-40. | ||||
| Ref 552410 | The evolving role of epoetin alfa in cancer therapy. Oncologist. 2004;9(1):97-107. | ||||
| Ref 552410 | The evolving role of epoetin alfa in cancer therapy. Oncologist. 2004;9(1):97-107. | ||||
| Ref 552410 | The evolving role of epoetin alfa in cancer therapy. Oncologist. 2004;9(1):97-107. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.